skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

The lowest-dose, extended-cycle combined oral contraceptive pill with continuous ethinyl estradiol in the United States: a review of the literature on ethinyl estradiol 20 µg/levonorgestrel 100 µg + ethinyl estradiol 10 µg

Review

(2159) Views  (553) Full article downloads

Authors: Sheila Krishnan, Jessica Kiley

Published Date August 2010 Volume 2010:2 Pages 235 - 239
DOI: http://dx.doi.org/10.2147/IJWH.S6437

Sheila Krishnan, Jessica Kiley

Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois, USA

Abstract: Extended-cycle oral contraceptives (OCs) are increasing in popularity in the United States. A new extended-cycle OC that contains the lowest doses of ethinyl estradiol (EE) and levonorgestrel (LNG) + continuous EE throughout the cycle is now available. It provides 84 days of a low-dose, combined active pill containing levonorgestrel 100 µg and ethinyl estradiol 20 µg. Instead of 7 days of placebo following the active pills, the regimen delivers 7 days of ethinyl estradiol 10 µg. Existing studies reveal a similar efficacy and adverse effect profile compared with other extended-regimen OCs. Specifically, the unscheduled bleeding profile is similar to other extended-cycle OCs and improves with the increase in the duration of use. Although lower daily doses of hormonal exposure have potential benefit, to our knowledge, there are no published studies indicating that this specific regimen offers a lower incidence of hormone-related side effects or adverse events. In summary, this new extended-cycle OC provides patients a low-dose, extended-regimen OC option without sacrificing efficacy or tolerability.

Keywords: continuous regimen, ethinyl estradiol, extended cycle, oral contraceptive






 

Other articles by Dr Jessica Kiley



Readers of this article also read:

Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS
The levonorgestrel-releasing intrauterine system: Safety, efficacy, and patient acceptability
Advances in labor analgesia
Emergency contraception: potential role of ulipristal acetate
New low-dose, extended-cycle pills with levonorgestrel and ethinyl estradiol: an evolutionary step in birth control
Erratum
Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility
Estradiol valerate and dienogest: a new approach to oral contraception